XCUR
Exicure, Inc. NASDAQ Listed May 22, 2018$1.91
Mkt Cap $12.2M
52w Low $1.71
2.6% of range
52w High $9.50
50d MA $2.93
200d MA $4.18
P/E (TTM)
-1.2x
EV/EBITDA
—
P/B
3.1x
Debt/Equity
0.0x
ROE
-126.0%
P/FCF
-1.4x
RSI (14)
28.40
ATR (14)
$0.41
Beta
4.01
50d MA
$2.93
200d MA
$4.18
Avg Volume
36.7K
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
2430 North Halsted Street · Chicago, IL 60614 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 28, 2026 | AMC | -18.60 | -0.29 | +98.4% | 2.97 | +8.4% | +7.4% | +4.4% | -6.6% | +1.6% | -6.3% | — |
| Mar 25, 2026 | AMC | -18.60 | -0.46 | +97.5% | 4.61 | -0.4% | +0.0% | -4.1% | +1.1% | -4.9% | -1.6% | — |
| Nov 7, 2025 | AMC | — | -0.39 | — | 3.96 | +1.0% | -2.3% | -3.6% | -3.5% | +1.4% | +1.6% | — |
| Aug 8, 2025 | AMC | — | -0.41 | — | 7.45 | -4.0% | +1.7% | -3.7% | -2.1% | -4.2% | -2.9% | — |
| Jun 27, 2025 | AMC | — | -0.45 | — | 5.89 | +7.1% | +19.5% | -13.4% | -2.3% | +13.8% | -4.6% | — |
| Mar 18, 2025 | AMC | — | -3.39 | — | 12.40 | -2.4% | +4.0% | +5.1% | +3.6% | -3.4% | -2.2% | — |
| Nov 14, 2024 | AMC | — | -0.57 | — | 3.18 | -4.7% | -8.8% | +35.9% | +47.7% | +92.3% | -2.9% | — |
| Aug 13, 2024 | AMC | — | -0.35 | — | 2.46 | -2.8% | -25.6% | -1.1% | -0.6% | +10.0% | -5.6% | — |
| Jun 17, 2024 | AMC | — | -0.50 | — | 1.58 | +2.5% | +4.4% | -1.2% | +4.3% | -3.5% | -3.7% | — |
| Jun 6, 2024 | AMC | — | -0.68 | — | 2.37 | -11.4% | -16.5% | -13.6% | +1.8% | +6.3% | -9.2% | — |
| May 16, 2024 | AMC | — | -3.05 | — | 2.60 | -2.7% | -4.6% | -4.0% | -0.4% | -1.7% | -3.9% | — |
| Mar 27, 2023 | AMC | -0.95 | 20.50 | +2257.9% | 4.50 | -4.4% | -10.9% | -2.7% | +6.9% | +4.6% | +0.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 16 | Chardan Capital | Maintains | Neutral → Neutral | — | $11.60 | $11.70 | +0.9% | -3.4% | +1.8% | -6.6% | -9.9% | -4.2% |
| Dec 13 | Chardan Capital | Downgrade | Buy → Neutral | — | $68.30 | $60.00 | -12.2% | -40.7% | -6.3% | +0.7% | +2.0% | -3.4% |
| Nov 23 | Chardan Capital | Maintains | Buy → Buy | — | $68.70 | $69.41 | +1.0% | -0.1% | +19.4% | -9.3% | -4.1% | -1.3% |
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $222.75 | $217.50 | -2.4% | -1.7% | +5.5% | -1.3% | +5.9% | +0.6% |
| Dec 18 | BMO Capital | Maintains | Outperform → Outperform | — | $237.00 | $271.50 | +14.6% | +25.9% | +5.5% | -8.1% | +2.6% | -2.5% |
| Sep 17 | Chardan Capital | Maintains | Buy → Buy | — | $306.75 | $319.50 | +4.2% | -0.7% | +1.0% | -6.8% | +0.5% | -3.6% |
| Nov 20 | Guggenheim | Maintains | Buy → Buy | — | $390.00 | $427.50 | +9.6% | +0.4% | +1.5% | -4.9% | +7.5% | -1.8% |
| Nov 6 | H.C. Wainwright | Maintains | Buy → Buy | — | $378.75 | $385.50 | +1.8% | -4.2% | +8.3% | -5.0% | -1.6% | +5.3% |
| Mar 26 | Chardan Capital | Maintains | Buy → Buy | — | $364.50 | $367.50 | +0.8% | -3.3% | +2.1% | -4.2% | +2.2% | +0.0% |
| Jul 11 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $847.50 | $862.50 | +1.8% | +1.9% | -1.9% | +0.0% | +0.0% | +1.6% |
No insider trades available.
8-K · 5.02
!!! Very High
Exicure, Inc. -- 8-K 5.02: Executive Change
Jun 30
8-K · 7.01
! Medium
Exicure, Inc. -- 8-K 7.01: Regulation FD Disclosure
Exicure regained Nasdaq compliance after filing its delayed Q1 2026 10-Q on May 29, 2026, following personnel and procedural changes that had caused the late submission.
Jun 1
NT 10-Q
!! High
Exicure, Inc. -- Late Quarterly Report -- Distress Signal
May 15
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The appointment of an experienced COO with 20+ years in enterprise software and data infrastructure suggests Xcur is strengthening operational execution and scaling capabilities, which could improve operational efficiency and support growth initiatives.
Apr 10
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Excercise Therapeutics faces legal proceedings requiring public disclosure; investors should monitor the stipulation details on the company's investor relations site to assess potential financial or operational impact.
Apr 2
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
XCUR's departure of an executive creates uncertainty about strategic direction and operational continuity, potentially pressuring the stock until a replacement is named and investor confidence is restored.
Mar 27
8-K
Unknown — 8-K Filing
Exicure's annual results announcement suggests potential significant developments warranting review of revenue, profitability, and clinical pipeline progress to assess whether the biotech company is advancing toward commercialization and investor value creation.
Mar 25
8-K · 5.02
!!! Very High
Exicure, Inc. -- 8-K 5.02: Executive Change
Exicure (XCUR) is transitioning leadership with Gyuyeob Lee becoming CEO while Jung Soo Kim departs, effective February 9, 2026, signaling potential strategic direction changes.
Feb 17
8-K · 5.02
!!! Very High
Exicure, Inc. -- 8-K 5.02: Executive Change
Exicure's leadership underwent significant restructuring with CEO Andy Yoo and CFO Seung Ik Baik resigning, replaced by new director appointments, signaling potential strategic shift for the gene-therapy company.
Feb 10
Valuation
Market Cap
$12.2M
Enterprise Value
$8.3M
P/E (TTM)
-1.24x
Forward P/E
—
PEG Ratio
0.14x
P/B
3.06x
P/S
—
P/FCF
-1.41x
EV/EBITDA
—
Shares Out
6.3M
Financials (TTM)
Revenue
$0
Net Income
-$9.8M
EBITDA
-$9.8M
Free Cash Flow
-$8.6M
Op Cash Flow
-$8.6M
EPS Basic
$-0.79
EPS Diluted
$-1.54
EPS Forward
—
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$14.0M
Total Liab.
$10.1M
Total Equity
$3.9M
Cash
$3.7M
LT Debt
$0
Book Value/Sh
$0.62
Debt/Equity
0.04x
Current Ratio
1.19
Quick Ratio
1.19
Returns & Growth
ROE
-126.0%
ROA
-35.2%
ROIC
-86.8%
Rev Growth YoY
-100.0%
EPS Growth YoY
+50.3%
Price Returns
2W
-11.2%
1M
-35.5%
3M
-52.5%
6M
-65.8%
12M
-70.5%
Technicals
52W High
$9.50
52W Low
$1.71
50d MA
$2.93
200d MA
$4.18
RSI (14)
28.40
ATR (14)
$0.41
Beta
4.01
Avg Volume
37K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$12.00
High
$12.00
Low
$12.00
Median
$12.00
Data updated apr 27, 2026 10:25am
· Source: financialmodelingprep.com